Optimal Treatment for Papillary Microcarcinoma

  • Mark D. Pace
  • R. Michael TuttleEmail author


The dramatic increase in the detection and diagnosis of papillary microcarcinomas has resulted in a huge increase in the number of thyroid cancer surgeries being done for very low-risk disease. While thyroid surgery is the cornerstone of the management of clinically significant thyroid cancer, the very low-risk nature of papillary microcarcinoma and the successful use of an active surveillance management approach by our Japanese colleagues have caused many clinicians and patients to question whether or not an immediate surgical approach to initial management is warranted in all cases. In this chapter we will review the risk factors associated with disease progression in papillary microcarcinoma, the expected outcomes after surgical resection, and the outcomes associated with active surveillance. Finally, we will provide clinical guidance with regard to proper selection of patients for either an immediate surgical management approach or an active surveillance observational management approach to very low-risk thyroid cancer.


Papillary thyroid microcarcinoma Thyroid microcarcinoma Papillary microcarcinoma Active surveillance 



The authors have no relevant conflicts of interest to disclose.


  1. 1.
    Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–91. doi: 10.1158/1055-9965.EPI-08-0960.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7. doi: 10.1001/jama.295.18.2164.CrossRefPubMedGoogle Scholar
  3. 3.
    Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317–22. doi: 10.1001/jamaoto.2014.1.CrossRefPubMedGoogle Scholar
  4. 4.
    Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004;150:133–9. doi: 10.1530/eje.0.1500133.CrossRefPubMedGoogle Scholar
  5. 5.
    Rego-Iraeta A, Pérez-Méndez LF, Mantinan B, Garcia-Mayor RV. Time trends for thyroid cancer in Northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid carcinoma. Thyroid. 2009;19:333–40. doi: 10.1089/thy.2008.0210.CrossRefPubMedGoogle Scholar
  6. 6.
    Ito Y, Miyauchi A. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid. Nat Clin Pract Endocrinol Metab. 2007;3:240–8. doi: 10.1038/ncpendmet0428.CrossRefPubMedGoogle Scholar
  7. 7.
    Roti E, Degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008;159:659–73. doi: 10.1530/EJE-07-0896.CrossRefPubMedGoogle Scholar
  8. 8.
    Londero SC, Krogdahl A, Bastholt L, et al. Papillary thyroid carcinoma in Denmark 1996–2008: an investigation of changes in incidence. Cancer Epidemiol. 2013;37:e1–6. doi: 10.1016/j.canep.2012.10.011.CrossRefPubMedGoogle Scholar
  9. 9.
    National Cancer Institute (no date) Surveillance, Epidemiology, and End Results Program (SEER). SEER Stat Fact Sheets: Thyroid Cancer. Available at:
  10. 10.
  11. 11.
    Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer. 1985;56:531–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Sturgeon C. Patients with thyroid cancer are at higher risk of Bankruptcy than patients with other types of cancer, or those without cancer. Clin Thyroidol. 2013;25:150–1.Google Scholar
  13. 13.
    Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr pract. 2007;13:498–512. doi: 10.4158/EP.13.5.498.CrossRefPubMedGoogle Scholar
  14. 14.
    Hay ID. Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract. 2007;13:521–33. doi: 10.4158/EP.13.5.521.CrossRefPubMedGoogle Scholar
  15. 15.
    Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34:1222–31. doi: 10.1007/s00268-009-0359-x.CrossRefPubMedGoogle Scholar
  16. 16.
    Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34:28–35. doi: 10.1007/s00268-009-0303-0.CrossRefPubMedGoogle Scholar
  17. 17.
    Ito Y, Miyauchi A, Kihara M, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24:27–34. doi: 10.1089/thy.2013.0367.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Lin KD, Lin JD, Huang MJ, et al. Clinical presentations and predictive variables of thyroid microcarcinoma with distant metastasis. Int Surg. 1997;82:378–81.PubMedGoogle Scholar
  19. 19.
    Lin HW, Bhattacharyya N. Survival impact of treatment options for papillary microcarcinoma of the thyroid. Laryngoscope. 2009;119:1983–7. doi: 10.1002/lary.20617.CrossRefPubMedGoogle Scholar
  20. 20.
    Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690–4.PubMedGoogle Scholar
  21. 21.
    Wada N, Duh Q-Y, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas. Ann Surg. 2003;237:399–407. doi: 10.1097/01.SLA.0000055273.58908.19.PubMedCentralPubMedGoogle Scholar
  22. 22.
    Lee J, Park JH, Lee C-R, et al. Long-term outcomes of total thyroidectomy versus thyroid lobectomy for papillary thyroid microcarcinoma: comparative analysis after propensity score matching. Thyroid. 2013;23:1408–15. doi: 10.1089/thy.2012.0463.CrossRefPubMedGoogle Scholar
  23. 23.
    He Q, Zhuang D, Zheng L, et al. The surgical management of papillary thyroid microcarcinoma: a 162-month single-center experience of 273 cases. Am Surg. 2012;78(11):1215–8.PubMedGoogle Scholar
  24. 24.
    Iyer NG, Morris LGT, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117:4439–46. doi: 10.1002/cncr.26070.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol. 1988;90:72–6.PubMedGoogle Scholar
  26. 26.
    Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastasis. Cancer. 1999;86:842–9. doi: 10.1002/(SICI)1097-0142(19990901)86:5<842::AID-CNCR21>3.0.CO;2-X.CrossRefPubMedGoogle Scholar
  27. 27.
    Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119:1135–9. doi: 10.1002/lary.20236.CrossRefPubMedGoogle Scholar
  28. 28.
    Cooper DS, Doherty GM, Haugen BR, et al. (2009) American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 19(11):1167–214. doi: 10.1089/thy.2009.0110.
  29. 29.
    Noguchi S, Yamashita H, Uchino S, Watanabe S. Papillary microcarcinoma. World J Surg. 2008;32:747–53. doi: 10.1007/s00268-007-9453-0.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:110–9. doi: 10.1093/annonc/mds230.CrossRefGoogle Scholar
  31. 31.
    Tuttle M, Ball DW, Byrd D, et al. NCCN clinical practice guidelines in oncology—Thyroid Carcinoma. 2013. NCCN.Google Scholar
  32. 32.
    Sugitani I, Fujimoto Y. Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab. 2010;95:4576–83. doi: 10.1210/jc.2010-0161.CrossRefPubMedGoogle Scholar
  33. 33.
    Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013;31:4046–53. doi: 10.1200/JCO.2013.49.1043.CrossRefPubMedGoogle Scholar
  34. 34.
    Pickles T, Ruether JD, Weir L, et al. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100:544–51. doi: 10.1111/j.1464-410X.2007.06981.x.CrossRefPubMedGoogle Scholar
  35. 35.
    Satge D, Grob JC, Pusel J, Methlin G. Thyroid microcarcinoma with a fatal outcome and 34 other unusually aggressive cases reported in the literature. Arch Anat Cytol Pathol. 1990;38:143–51.PubMedGoogle Scholar
  36. 36.
    Lissak B, Vannetzel JM, Gallouedec N, et al. Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. J Endocrinol Invest. 1995;18:813–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Akazaki K, Kajita A, Higo N. An autopsy case of microscopic sized thyroid carcinoma characterized by generalized bone metastases. Syujyutu. 1960;14:66–71.Google Scholar
  38. 38.
    Patchefsky AS, Keller IB, Mansfield CM. Solitary vertebral column metastasis from occult sclerosing carcinoma of the thyroid gland: report of a case. Am J Clin Pathol. 1970;53:596–601.PubMedGoogle Scholar
  39. 39.
    Levi E. Carcinoma of thyroid with metastases to lungs. N Y State J Med. 1975;75:1544–6.PubMedGoogle Scholar
  40. 40.
    Boehm T, Rothouse L, Wartofsky L. Metastatic occult follicular thyroid carcinoma. JAMA. 1976;235:2420–1.CrossRefPubMedGoogle Scholar
  41. 41.
    Jancić-Zguricas M, Janković R. Occult papillary carcinoma of the thyroid gland revealed by cancer pericarditis. Pathol Res Pract. 1986;181:761–6. doi: 10.1016/S0344-0338(86)80053-X.CrossRefPubMedGoogle Scholar
  42. 42.
    Michie HR, O’Bryan-Tear CG, Marsh H, Glazer G. Cerebral metastases from occult papillary carcinoma of the thyroid. Br J Surg. 1987;74:647.CrossRefPubMedGoogle Scholar
  43. 43.
    (2013) 83rd Annual Meeting of the American thyroid association short call abstracts. Thyroid 23:A-115–A-121. doi:  10.1089/
  44. 44.
    Anandadas CN, Clarke NW, Davidson SE, et al. Early prostate cancer—which treatment do men prefer and why? BJU Int. 2011;107:1762–8. doi: 10.1111/j.1464-410X.2010.09833.x.CrossRefPubMedGoogle Scholar
  45. 45.
    Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what’s important. J Gen Intern Med. 2000;15:694–701.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Gorin MA, Soloway CT, Eldefrawy A, Soloway MS. Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology. 2011;77:588–91. doi: 10.1016/j.urology.2010.10.039.CrossRefPubMedGoogle Scholar
  47. 47.
    Oliffe JL, Davison BJ, Pickles T, Mróz L. The self-management of uncertainty among men undertaking active surveillance for low-risk prostate cancer. Qual Health Res. 2009;19:432–43. doi: 10.1177/1049732309332692.CrossRefPubMedGoogle Scholar
  48. 48.
    Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg. 2004;28:498–501. doi:10.1007/s00268-004-7192-z.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of Endocrinology and DiabetesThe AlfredMelbourneAustralia
  2. 2.Endocrinology Service, Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations